Bio-hybrid nanovesicles with multimodal antioxidant and immunomodulatory functions attenuate acute kidney injury Authors: Wenzhe Chen, Haitao Yuan, Haitao Liu, Min Zou, Junhui Chen, Yanting Liang, Xiaoxian Wang, Jingbo Ma, Mengyun Hou, Jinyue He, Wei Xiao, Di Gu, Guohua Zeng, Jigang Wang Published: 2026 ABSTRACT Oxidative stress, marked by a disparity between the generation of reactive oxygen species (ROS) and the body’s antioxidant defenses, is crucial in the development of acute kidney injury (AKI), where excessive ROS accumulation drives tubular epithelial cell damage and inflammatory cascades. Dysregulated inflammatory immunity further exacerbates tissue injury, highlighting the need for integrated strategies that simultaneously regulate oxidative defense and inflammatory immune activation. Given this rationale, we developed bio-hybrid nanovesicles (ES-EVs) by integrating ES NPs of epigallocatechin-3-gallate (EGCG) and selenomethionine (SeMet) into extracellular vesicles derived from human umbilical cord mesenchymal stem cells (hUMSC-EVs). In this study, ES NPs were synthesized, preserving the biological activities of EGCG and SeMet while enhancing their stability and bioavailability. Furthermore, the integration of the potent antioxidant and anti-inflammatory properties of ES NPs with the passive targeted delivery and immunomodulatory functions of hUMSC-EVs offers a promising strategy for the treatment of AKI. In vitro evaluation confirmed that ES-EVs were able to mitigate oxidative stress, protect mitochondria, inhibit apoptosis and polarize macrophages toward an anti-inflammatory phenotype, thereby preventing excessive inflammatory cascades. In vivo experiments demonstrated that ES-EVs effectively enhanced renal function, repaired damaged renal tissue and decreased apoptosis. ES-EVs aid renal function recovery by inhibiting oxidative stress, maintaining inflammatory homeostasis and reprogramming the immune microenvironment. RNA sequencing analysis demonstrated that ES-EVs can alleviate cisplatin induced oxidative stress and DNA damage, and at the same time play an anti-inflammatory role. In summary, this study has established a bionic hybrid nanovesicular with multifunctional therapeutic properties, which lays the foundation for the clinical translation of management of AKI.Graphical Abstract In this study, we engineered biohybrid nanovesicles (ES-EVs) through integration of hUMSC-EVs and EGCG-SeMet nanoparticles (ES NPs), demonstrating multimodal therapeutic efficacy against AKI via coordinated oxidative stress regulation, inflammatory homeostasis maintenance and immune microenvironment remodeling. ES-EVs offer cytoprotection by scavenging excessive intracellular ROS and support inflammatory homeostasis by regulating macrophage polarization. Notably, when compared to the individual use of ES NPs and hUMSC-EVs, the synthesized ES-EVs demonstrated a superior ability to modulate inflammation. In vivo experiments demonstrated that ES-EVs have the potential to ameliorate AKI by inhibiting the cGAS-STING signaling pathway and modulating macrophage phenotypes. To investigate the potential applications of ES-EVs, a series of flow cytometry experiments were conducted to assess their immunomodulatory effects in a murine model of AKI. The results showed that ES-EVs could not only regulate macrophage polarization, but also inhibit the transformation of DCs to a mature state and inhibit CD8+ activation. This biocompatible strategy using extracellular vesicle-natural product complexes shows promise for AKI treatment. Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12951-026-04601-0. Introduction Acute kidney injury (AKI) is characterized by a rapid decrease in kidney function, indicated by a rise in serum creatinine and/or a drop in urine production [1]. Acute kidney injury impacts 10%–20% of patients in hospitals and up to 50% of individuals in intensive care units, with severe cases associated with mortality rates ranging from 30% to 50% [2, 3]. Current therapeutic strategies primarily focus on pharmacological intervention and supportive measure which includes fluid resuscitation, electrolyte management, and renal replacement therapy for refractory cases [4]. The limitations of pharmacological interventions stem from systemic drug distribution, rapid clearance and inability to target renal parenchyma effectively [5]. Currently, there is a shortage of effective disease-modifying agents that target the mechanisms by which reactive oxygen species (ROS) and inflammatory cytokines induce renal tubular injury [6]. As a result, clinicians are forced to focus on symptom management rather than targeting the underlying cause of the condition. This therapeutic gap underscores the urgent need for novel strategies that combine the targeting of inflammation with robust antioxidant capacity to improve clinical outcomes. Recent advances in AKI pathophysiology have elucidated the pivotal role of oxidative stress, with particular emphasis on renal vulnerability due to the organ’s high metabolic rate and abundant mitochondrial content [7]. Mitochondrial dysfunction in AKI progression leads to cytoplasmic accumulation of mitochondrial DNA (mtDNA), activating the cGAS-STING signaling pathway via binding to cyclic GMP-AMP synthase (cGAS), promoting the expression of type I interferons (IFN-I) and other pro-inflammatory cytokines [8]. Importantly, increased IFN-I production would promote macrophage differentiation to a proinflammatory M1 phenotype, with similarly increased secretion of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [9]. Macrophages act as essential controllers of inflammation, displaying functional flexibility by alternating between M1 pro-inflammatory and M2 anti-inflammatory phenotypes [10]. This polarization imbalance manifests clinically as sustained M1 predominance in AKI microenvironments, correlating with histopathological findings of neutrophil infiltration and tubular atrophy [11]. Current immunomodulatory strategies targeting this axis face dual challenges: (1) achieving selective M1 suppression without compromising M2-mediated repair; (2) circumventing systemic immunosuppression risks inherent to broad-spectrum cytokine inhibition. Emerging strategies that combine ROS scavenging with macrophage phenotype-specific modulation show synergistic efficacy in preclinical models of AKI. Compounds derived from nature that can manage oxidative stress and control inflammation are showing potential as therapies for sterile inflammatory diseases [12]. Previous studies have indicated that Epigallocatechin-3-gallate (EGCG), a polyphenolic catechin commonly found in green tea, shows significant antioxidant and anti-inflammatory effects [13, 14]. However, clinical translation is hindered by EGCG’s physicochemical limitations: poor aqueous solubility and rapid autoxidation at physiological pH, resulting in < 5% oral bioavailability [15]. The development of nanomedicine through the coupling or coordination of small molecular amino acids with EGCG offers a solution to the limitations associated with EGCG monomers [16, 17]. Selenomethionine (SeMet) is an organic form of selenium naturally found in dietary sources such as nuts, cereals and animal products. As an essential constituent of selenoproteins-including glutathione peroxidases and thioredoxin reductases-SeMet plays a critical physiological role in maintaining cellular redox homeostasis, protecting against oxidative damage and regulating inflammatory responses. Unlike inorganic selenium salts such as sodium selenite, SeMet offers higher bioavailability and lower toxicity, making it an attractive candidate for biomedical applications. Therefore, the incorporation of SeMet is expected to confer several advantages: (i) synergistic alleviation of oxidative stress in combination with EGCG; (ii) improved physicochemical stability of the nanoparticles under physiological conditions through self‑assembly with EGCG; (iii) selenium supplementation, which may help mitigate oxidative stress‑driven inflammation in AKI [18, 19]. Despite advancements in nanomedicine-based treatment strategies for AKI, a significant technical challenge persists: the development of efficient delivery systems that enable drug accumulation in the kidney [20]. Such systems are crucial for enhancing drug efficacy and biosafety by improving the stability of drug molecules and ensuring renal localization. Immune dysfunction is pivotal in AKI pathogenesis, highlighting the need to maintain immune microenvironment homeostasis to balance innate and adaptive immunity [21]. Therefore, effectively managing non-infectious inflammation, such as AKI, necessitates addressing the challenges associated with scavenging oxygen free radicals, maintaining inflammatory homeostasis and remodeling the immune microenvironment [22, 23]. Human umbilical mesenchymal stem cell-derived extracellular vesicles (hUMSC-EVs) present a promising integrative approach owing to their significant immunomodulatory properties, biocompatibility and minimal immunogenicity [24–26]. To improve the treatment of AKI, it is crucial to develop bionic nanomedicines with better inflammation targeting and biocompatibility, using mesenchymal stem cell-derived exosomes. In this study, we engineered biohybrid nanovesicle (ES-EV) by integrating hUMSC-EVs with EGCG-SeMet nanoparticle (ES NP) as a strategy to simultaneously regulate oxidative stress, inflammatory homeostasis, and the immune microenvironment in AKI (Scheme 1A-B). We sought to investigate whether this biohybrid platform could exert coordinated antioxidant and immunomodulatory effects in the context of AKI. This biocompatible strategy provides a foundation for exploring extracellular vesicle-based nanotherapeutics in the context of AKI. Scheme 1The schematic diagram of bio-hybrid nanovesicles ES-EV for the treatment of AKI. A) The Synthesis of ES-EVs and regulation of oxidative stress in vitro.B) ES-EVs treatment of acute kidney injury in mice and modulation of the immune microenvironment. Abbreviations: BUN (blood urea nitrogen), CRE (creatinine), EGCG (Epigallocatechin-3-gallate), ES NP (EGCG-SeMet nanoparticle), EV (Extracellular vesicle), mtDNA (mitochondrial DNA), ROS (reactive oxygen species), SeMet (Selenomethionine), SOD (Superoxide dismutase), tDC (tolerant Dendritic cell) The schematic diagram of bio-hybrid nanovesicles ES-EV for the treatment of AKI. A) The Synthesis of ES-EVs and regulation of oxidative stress in vitro.B) ES-EVs treatment of acute kidney injury in mice and modulation of the immune microenvironment. Abbreviations: BUN (blood urea nitrogen), CRE (creatinine), EGCG (Epigallocatechin-3-gallate), ES NP (EGCG-SeMet nanoparticle), EV (Extracellular vesicle), mtDNA (mitochondrial DNA), ROS (reactive oxygen species), SeMet (Selenomethionine), SOD (Superoxide dismutase), tDC (tolerant Dendritic cell) Methods Materials C57BL/6 mice were purchased from GemPharmatech LLC. (Guangdong, China). TaKaRa (Dalian, China) provided the TB Green and PrimeScript RT reagent Kit. RNase-free water was purchased from Bio-sharp (Anhui, China). Epigallocatechin-3-gallate (EGCG) was obtained from Meilun Bio (Dalian, China). SeMet was purchased from MCE Biotechnology (China). ABTS, DPPH and O2− scavenging kit were obtained from Solarbio Science & Technology Co., Ltd. The kits for BUN, CRE, ALT and AST were obtained from Nanjing Jiancheng Bioengineering Institute. ELISA kits were purchased from United Biosciences. All of the schematic diagrams were created by Figdraw. Preparation of EGCG-SeMet (ES NPs) and ES-EV Preparation of EGCG-SeMet (ES NPs) EGCG (22.875 mg) and SeMet (3.26 mg) were added in deionized water (10 mL). Then, 75 µL of formaldehyde solution (4%) was added to the mixed solution at room temperature (25 ℃). The ES NPs were acquired through centrifugation at 12,000 g for 5 min following 5 h of continuous vigorous magnetic stirring in the dark, and subsequently purified. Preparation of ES-EV ES-EVs were prepared by physical mixing of ES NPs and hUMSC-EVs. Briefly, ES NPs (100 µL, 10 mg/mL) and hUMSC-EVs (100 µL, 1 mg/mL) were combined in 800 µL of deionized water, gently vortexed for 10 s, and incubated overnight (16 h) at 4 °C in the dark with mild shaking (100 rpm) to facilitate membrane integration. The formation of ES-EV complexes was confirmed by transmission electron microscopy (TEM) and dynamic light scattering (DLS). Extraction and characterization of EV The EVs were extracted by gradient centrifugation. The supernatant from the cells was centrifuged at 500 g at 4 °C to eliminate dead cells. The supernatant was collected and initially centrifuged at 12,000 g for half hour at 4 °C to eliminate cell debris. It was then subjected to a second centrifugation at 1 × 105 g for an hour at 4 °C to pellet the EVs. The precipitates were resuspended in PBS after discarding the supernatant and the previous step was repeated. The precipitates were suspended in a minimal volume of PBS and stored at − 80 °C until needed. NTA assessed the size and concentration of extracted EVs. Protein concentration of EVs was measured using a BCA protein assay kit. Western blotting analysis was employed to identify various surface markers of human umbilical mesenchymal stem cells (hUMSCs) and extracted EVs, such as Calnexin, CD9, CD44, and β-actin. TEM was used to observe the morphologies of the EVs. Reactive oxygen and nitrogen species (RONS)-scavenging capacity of ES-EV Determination of free radical scavenging capacity The free radical scavenging capacity of ES-EV was assessed using ABTS and DPPH assay kits. The ABTS and peroxidase working solutions were prepared and combined beforehand following the manufacturer’s guidelines. Then different concentration (0.125, 0.25, 0.5, 1 mg/mL) of ES-EV were added to the reaction system. After sitting at room temperature for 6 min, the absorbance of the mixture was measured at 405 nm using multifunctional microplate reader (Tecan Spark). Similarly, DPPH working solution containing DPPH in absolute ethanol was prepared and mixed well with different concentration of ES-EV (0.25, 0.5, 1 and 1.5 mg/mL) as described above. The absorbance of each reaction solution was detected at 515 nm with multifunctional microplate reader (Tecan Spark). Measurement of O2− scavenging capacity The O2− scavenging capacity of ES-EV was evaluated by an O2− activity assay kit, following the manufacturer’s instructions. The reaction mixture was incubated at 37 °C for 10 min, after which the absorbance of both the blank and test solutions was measured at 530 nm, recorded as AB and AT, respectively. The O2− scavenging rate was calculated following the equation: D% = (AB – AT) ÷ AB × 100%. All experiments were performed in duplicates. Measurement of SOD scavenging The ability of ES-EV to scavenge superoxide anions was assessed using a SOD assay kit. The reaction setup and conditions followed the kit’s guidelines, and the mixture was maintained at 25 °C for 20 min. The absorbance values of blank solution, blank control solution, test solution, and test blank solution at 450 nm were recorded as AB, ABC, AT and ATC respectively. The SOD inhibition rate was calculated following the equation: D% = ((AB – ABC) – (AT – ATC)) ÷ (AB – ABC) × 100%. All experiments were performed in duplicates. Cell culture HK-2 cells (Human kidney, RRID: CVCL_0302) which obtained from Procell Life Science & Technology Co., Ltd, were cultured in DMEM/F-12 medium. RAW 264.7 cells (RRID: CVCL_0493) which obtained from KeyGEN Biotech Co., Ltd, were cultured in DMEM medium. The hUMSCs (RRID: CVCL_B5SZ) were purchased from Cyagen Biosciences Inc. (Guangzhou, China; catalog number HUXUC-01001; www.oricellbio.cn). According to the supplier, the hUMSCs were isolated from the umbilical cord of a healthy full-term donor with written informed consent, and the isolation procedure was approved by the supplier’s Institutional Review Board. Donors were screened for infectious diseases (HIV, HBV, HCV, and syphilis) and were negative for all tested pathogens. The cells were authenticated by the supplier using surface marker analysis (CD73⁺, CD105⁺, CD29⁺, and CD34⁻, CD45⁻, CD11b⁻) and differentiation potential assays. The cells were used between passages 3–6. All cells were cultured in a 37 °C, 5% CO2 incubator with 10% FBS and without antibiotics. The in vitro injury model was established by treating HK-2 cells with 1.2 mM H2O2 for 24 h. Treatment with ES-EVs (20 µg/mL) was administered simultaneously with H₂O₂, and cells were incubated for 24 h. Cell viability assay Cell viability was assessed by seeding HK-2 cells at 10,000 cells/well in 96-well plates, followed by the addition of 1.2 mM H2O2 with varying concentrations of ES-EV (5, 10, and 20 µg/mL) for 24 h. RAW 264.7 cells were plated at 2 × 104 cells per well in 96-well plates, followed by the addition of ES-EV at concentrations of 5, 10 and 20 µg/mL for 24 h. After completion of incubation, the medium in the Wells was removed, and 100 µL of CCK8 solution was added to the Wells and detected at 450 nm wavelength after 1.5 to 3 h of incubation. Cellular uptake HK-2 cells were cultured overnight in 96-well plates at a density of 10,000 cells per well and subsequently incubated for 0, 1, 3, 6, 9 and 24 h with 20 µg/mL Cy5@ES-EV (as this concentration of ES-EV had the best cytoprotective properties). The uptake of ES-EV by the cells was analyzed using laser confocal microscopy and flow cytometry. Cellular ROS detection HK-2 cells were exposed to 1.2 mM H2O2 alone or combined with ES-EV (5, 10, and 20 µg/mL) for 24 h. Subsequently, the cells were washed with PBS prior to observation. Cells were incubated with 20 µM DCFH-DA for 30 min at 37 °C, followed by PBS washing, to detect cellular ROS. Fluorescence images were collected using Fluorescence microscopy (Nikon-CHGFI). The average fluorescent intensity was analyzed with ImageJ (version 1.8.0). Live/dead cell staining assay The Calcein-AM/PI double stain kit was employed to differentiate between live and dead cells in the live/dead cell staining assay. HK-2 cells were exposed to 1.2 mM H2O2, with or without ES-EV (5, 10, and 20 µg/mL), for 24 h. Live/dead cell staining was performed using Calcein-AM and PI for half hour. Subsequently, the cells were rinsed with PBS prior to observation. Fluorescence images were collected using Fluorescence microscopy (Nikon-CHGFI). The average fluorescent intensity of every single cell was analyzed with ImageJ (version 1.8.0). Measurement of mitochondrial membrane potential HK-2 cells were exposed to 1.2 mM H2O2 alone or combined with ES-EV for 24 h, followed by staining of HK-2 cells with 500 µL JC-1 for an hour at 37 °C. Subsequently, the cells were rinsed with PBS prior to observation. Fluorescence images were collected using Fluorescence microscopy (Nikon-CHGFI). The average fluorescent intensity of every single cell was analyzed with ImageJ (version 1.8.0). Flow cytometry analysis of cell apoptosis and JC-1 staining Cell apoptosis HK-2 cells were seeded in 6-well plates at a density of 3.5 × 105 cells per well for 24 h. The medium was then replaced with fresh media containing 1.2 mM H2O2, with or without the addition of 5, 10–20 µg/mL ES-EV. Following a 24-hour incubation, cells were harvested and treated with an Annexin V-FITC/PI apoptosis detection kit. JC-1 staining HK-2 cells were seeded in 6-well plates at a density of 3.5 × 105 cells per well for 24 h. The medium was then replaced with fresh media containing 1.2 mM H2O2, with or without the addition of 5, 10–20 µg/mL ES-EV. Following a 24-hour incubation, HK-2 cells were stained with 500 µL JC-1 for 1 h at 37 °C. Subsequently, the cells were rinsed with PBS. All of the flow cytometry analysis in the Sect. 2.10.2 were conducted using the cytoFLEX flow cytometer (Beckman Coulter). Western blotting Total protein extraction was conducted utilizing RIPA Lysis Buffer (Beyotime Biotechnology). Specifically, 1 mL of the buffer was administered to each well of a six-well plate to ensure comprehensive cell lysis and facilitate the collection of lysates. Proteins were subsequently isolated through centrifugation at 12,000 g and 4 °C for 30 min. Equivalent quantities of protein were resolved on 7.5%–10% polyacrylamide gels and subsequently transferred onto polyvinylidene fluoride (PVDF) membranes with pore sizes of either 0.45 μm–0.22 μm. The membranes were blocked with 5% non-fat milk or bovine serum albumin (BSA) for 2 h, followed by overnight incubation at 4 °C with primary antibodies at dilutions ranging from 1:200 to 1:5,000. Thereafter, the membranes were incubated for 1.5 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (Bioss Antibodies) diluted 1:10,000 in the blocking solution. Following three washes of 10 min each with TBST, the membranes were treated with Superstar ECL Western Blotting Substrate (ECOTOP Scientific) and visualized via chemiluminescence after a 30-second incubation. Finally, band intensities were quantified using ImageJ software. In vivo experiments AKI model experiments All animal procedures were approved by the Institutional Animal Care and Use Committee of Shenzhen People’s Hospital (Approval No. AUP-221015-LZJ-0596-01). Mice were received a single intraperitoneal injection of cisplatin (20 mg/kg) in sterile physiological saline. ES-EV (2 mg/kg/ day) were injected via tail vein at 1, 24 and 48 h after cisplatin administration to determine the effect on the recovery of renal function in mice. Evaluation of in vivo experiments Mouse body weight was recorded daily for four consecutive days, starting from Day 0. The relative body weight for each animal was calculated as the ratio of the weight on a given day to that on Day 0, and weight change curves were plotted for each group based on the relative values over the four‑day period. At 72 h after cisplatin administration, retroorbital blood and tissue samples were collected. The right kidney was fixed in 4% formaldehyde and processed for paraffin‑embedded histological sections, whereas the left kidney was snap‑frozen for subsequent RNA sequencing. Peripheral blood was centrifuged, and the resulting serum was used for measurements of BUN, CRE, ALT and AST, as well as for enzyme‑linked immunosorbent assay (ELISA). Evaluation of biological safety Peripheral blood was collected for biosafety assessment. Specifically, 0.3 mL of a 4% murine erythrocyte suspension (v/v) was mixed with an equal volume of ES-EV solutions at various concentrations. Following a 4-hour incubation at room temperature, the mixtures were spun at 2500 rpm for 2 min, and the absorbance of the resulting supernatant was measured at 542 nm with a microplate reader. The remaining blood sample was centrifuged to obtain serum, which was then used to measure levels of BUN, CRE, ALT, and AST in mice. The sources of the kits and the experimental procedures were identical to those described in Sect. 2.12.2. Hematoxylin and eosin (H&E) staining Kidney tissue samples were preserved in 4% paraformaldehyde, embedded in paraffin, and sliced into 4 micrometer thick sections. Using Case Viewer software, randomly selected fields were examined at higher magnification to assess tubular injury, including luminal dilation, epithelial necrosis, cast formation, and loss of the brush border. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining Paraffin-embedded kidney tissue sections underwent sequential dewaxing with xylene and a graded ethanol series. Post-rehydration, the sections were incubated with DNase-free proteinase K at a concentration of 20 µg/mL for 20 min at 37 °C, followed by permeabilization with 0.1% Triton X-100 for an additional 20 min. Subsequently, the terminal deoxynucleotidyl transferase (TdT) reaction cocktail was applied, and the sections were maintained at 37 °C for 2 h in darkness. Following three washes with PBS, nuclear counterstaining was conducted using 4′,6-diamidino-2-phenylindole (DAPI) for 10 min. Fluorescence images were then acquired using a fluorescence microscope. Transcriptome sequencing (RNA-seq) analysis Total RNA was extracted from kidney tissue samples, with four samples per experimental group, utilizing the QIAzol Lysis Reagent (Qiagen) following the protocol recommended by the manufacturer. The RNA quality and concentration were assessed using a Nanodrop2000 spectrophotometer, while RNA integrity was confirmed through agarose gel electrophoresis and RIN analysis conducted with an Agilent5300 system. Specimens were considered suitable for library preparation only if they met the following criteria: an OD260/280 ratio between 1.8 and 2.2, a RIN value of at least 6.5, a 28 S:18 S ratio of at least 1.0, and an RNA concentration of at least 30 ng/µL. The raw sequencing data were processed using fastp software (version 0.22.0) to remove low-quality reads. The high-quality sequences obtained were then aligned to the mouse reference genome (mm10-2020-A) using HISAT2 (version 2.2.1). Gene and transcript quantification was performed based on the alignment results using featureCounts (version 2.0.3). The R software package edgeR (version 3.38.4) was employed for data normalization and the identification of differentially expressed genes. Functional enrichment analysis of the differentially expressed genes was conducted using clusterProfiler (version 4.9.1). Statistical analysis In the present study, each experiment was conducted at least three times, and the results are expressed as the mean ± standard deviation. For analyses involving three or more groups, a one-way analysis of variance (ANOVA) was employed. Statistical analyses were performed using FlowJo (version 10.8.1), ImageJ (version 1.8.0), and GraphPad Prism Software (version 9.0). A p-value of less than 0.05 was considered indicative of statistical significance. Results and discussion The synthesis and characterization of ES NPs To regulate oxidative stress and maintain inflammatory homeostasis, we selected the natural green tea extract EGCG and the natural amino acid SeMet to construct the nanomedicine. Briefly, ES NPs were synthesized by stirring solutions of EGCG and SeMet at room temperature for 5 h in the presence of trace amounts of formaldehyde, followed by centrifugation and purification (Fig. 1A). TEM analysis demonstrated that the ES NPs possessed a consistent spherical morphology (Fig. 1B). Figure 1C illustrates that the particle size of the ES NPs, measured by DLS, was roughly 129.85 ± 4.06 nm. Moreover, high-angle annular dark field (HAADF) imaging and energy-dispersive X-ray spectroscopy (EDS) mapping (Fig. 1D and Fig. S1) confirmed a uniform distribution of C, N, O and Se within the ES NPs, verifying the successful incorporation of SeMet. Additionally, Fourier transform infrared (FT-IR) spectroscopy was employed to further substantiate the incorporation of SeMet. As illustrated in Fig. S2, the absorption peak of -OH shift from 3355 cm⁻¹ to 3404 cm⁻¹, along with the carbonyl (C = O) shift from 1691 cm⁻¹ to 1692 cm⁻¹, indicating successful synthesis of ES NP. The pathophysiological mechanisms underlying various forms of AKI are intricately linked to an overproduction of ROS [27]. SOD serves as a primary antioxidant enzyme, playing a crucial role in mitigating the formation of free radicals within cells. The enzyme SOD converts superoxide anion radicals (O2−) into hydrogen peroxide and molecular oxygen (O2) [28]. As illustrated in Fig. 1E, an increase in the concentration of ES NPs (0.2 − 0.8 mg/mL) corresponded with an elevation in SOD activity from 60% to nearly 100%. We evaluated the effectiveness of ES NPs in neutralizing the hydroxyl radical (OH−) and O2−. The data shown in Fig. 1F-G reveal that the scavenging of OH− and O2− was effective and varied with concentration. Beyond ROS, reactive nitrogen species (RNS) also pose a significant threat to oxidative stress. Therefore, the capability of ES NPs to scavenge RONS is crucial for protecting renal tissues from oxidative damage. In this context, we conducted an extensive investigation into the free radical scavenging activity of ES NPs across various concentrations. ABTS and DPPH assays, which are commonly used to evaluate the RNS scavenging potential of nanomedicines, were employed. The ABTS scavenging rate markedly increased from 30% to 90% as the concentration of ES NPs was elevated from 0.125 to 1 mg/mL (Fig. 1H and Fig. S3). DPPH was reduced by 80% at a concentration of 1.5 mg/mL, demonstrating concentration dependence (Fig. 1I). The findings indicated that ES NPs possess exceptional and swift free-radical scavenging capabilities. Electron spin resonance (ESR) provided a more intuitive visualization of the reduction in radical amplitude. The ESR spectrum exhibited a distinct multiple peak profile. The presence of ES NPs significantly reduced the OH− signal peak, demonstrating their high sensitivity for OH− scavenging (Fig. 1J). Incorporating ES NPs resulted in a reduction of the O2−’s peak intensity in the ESR spectrum, suggesting its efficient consumption (Fig. 1K). Likewise, the peak of the DPPH− ESR signal notably diminished with ES NPs, demonstrating their potent ability to scavenge DPPH− (Fig. 1L). The results validate the superior multiantioxidant and SOD-enzyme activities of ES NPs against diverse RONS in vitro. The synthesis and characterization of ES-EVs We collected hUMSC culture medium, which was cultured in serum-free DMEM for 48 h, and isolated EVs using an ultracentrifugation method to eliminate the influence of serum-derived exosomes (Fig. 1M). As depicted in Fig. S4, TEM revealed the presence of cup-shaped vesicles. Subsequent analysis using nanoparticle tracking analysis (NTA) demonstrated a unimodal size distribution, with a median diameter of 162.8 nm, indicating homogeneity (Fig. S5). TEM further confirmed the successful assembly of EVs and ES NPs (Fig. 1N). The NTA results showed a notable increase in nanoparticle size after modification of EVs with ES NP, from about 162.8 nm to 175.1 nm, aligning with DLS measurements (Fig. S6-7). Upon binding of ES NPs to EVs, the zeta potential decreased from -15.2 mV to -27 mV (Fig. S8). Western blotting (WB) confirmed the presence of the EVs positive marker (CD9), the absence of the negative marker (Calnexin), and the presence of CD44, indicating successful isolation of purified EVs (Fig. 1O). SDS-PAGE analysis revealed a similarity in the protein composition of EVs and ES-EVs (Fig. 1P). In summary, ES NPs with outstanding multi-antioxidant properties were successfully integrated into EVs, creating bio-hybrid nanovesicles called ES-EVs. Fig. 1The synthesis and characterization of ES-EVs. A) Diagram depicting the synthesis process of ES-EVs. B) TEM image illustrating typical ES NPs. C) DLS of ES NPs. D) EDS images of ES NPs. E) SOD activity of ES NPs. F-I) Evaluation of ES NPs’ free radical scavenging capacity against OH− (F), O2− (G), ABTS (H) and DPPH (I), respectively. J-L) Radical adducts trapped by ES NPs on OH− (J), O2− (K) and DPPH− (L) are shown in the ESR spectra. M) Diagrammatic representation of the EVs extraction process. N) Representative TEM image of ES-EVs. O) WB of hUMSC, EVs and ES-EVs. P) SDS-PAGE analysis was conducted on hUMSC, EVs and ES-EVs samples. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 The synthesis and characterization of ES-EVs. A) Diagram depicting the synthesis process of ES-EVs. B) TEM image illustrating typical ES NPs. C) DLS of ES NPs. D) EDS images of ES NPs. E) SOD activity of ES NPs. F-I) Evaluation of ES NPs’ free radical scavenging capacity against OH− (F), O2− (G), ABTS (H) and DPPH (I), respectively. J-L) Radical adducts trapped by ES NPs on OH− (J), O2− (K) and DPPH− (L) are shown in the ESR spectra. M) Diagrammatic representation of the EVs extraction process. N) Representative TEM image of ES-EVs. O) WB of hUMSC, EVs and ES-EVs. P) SDS-PAGE analysis was conducted on hUMSC, EVs and ES-EVs samples. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 In vitro analysis of ES-EV demonstrated its capabilities in cell endocytosis, ROS scavenging and anti-apoptotic functions To assess the capacity of ES-EV to regulate oxidative stress, we conducted in vitro experiments using HK-2 cells (Fig. 2A). As depicted in Fig. S9, demonstrates that ES-EV maintains excellent biocompatibility, showing no significant toxicity. Cellular endocytosis is crucial for nanomedicine efficacy; thus, we assessed ES-EV internalization at different time intervals using confocal laser scanning microscopy (CLSM). For visualization, ES-EV were tagged with the fluorescent probe Cyanine 5 (Cy 5), forming Cy 5@ES-EV and cell nuclei were stained with DAPI. Figure 2B demonstrates that Cy 5@ES-EV internalization occurs in a time-dependent manner and is localized within the cytoplasm. Flow cytometry analysis further revealed that the fluorescence intensity of Cy 5@ES-EV reached its maximum at 9 h (Fig. 2C). These findings unequivocally confirm the ability of HK-2 cells to internalize ES-EV, demonstrating a progressive increase in uptake over time. Cisplatin is commonly employed in solid tumor treatment, however, its nephrotoxicity adversely impacts clinical outcomes [29]. Research has shown that cisplatin mainly causes kidney injury by generating oxidative stress [28]. To assess the protective role of ES-EV in AKI, HK-2 cell injury was initially induced by mimicking cisplatin-induced oxidative stress using varying concentrations of hydrogen peroxide (0.8–1.4 mM). Based on cell viability assays, 1.2 mM H2O2 was selected to induce tubular damage in subsequent experiments, serving as the positive control group (Fig. S10). As illustrated in Fig. 2D, exposure to H2O2 resulted in a 33% reduction in HK-2 cell viability. Conversely, ES-EV treatment improved cell viability in a concentration-dependent manner. Furthermore, Fig. S11 revealed that untreated HK-2 cells appeared relatively homogeneous and intact, whereas treatment with H2O2 significantly reduced cell numbers and resulted in visibly wrinkled morphology. Under the influence of ES-EV, there was a notable increase in cell proliferation and an improvement in cellular morphology, with the protective effects becoming more pronounced as the concentration of ES-EV increased. Notably, the 20 µg/mL ES-EV group exhibited the most substantial protective effect. The results demonstrate that ES-EV significantly protects HK-2 cells from oxidative stress-induced damage. Subsequently, we further investigated the reduction of ROS within the cells. As depicted in Fig. 2E, HK-2 cells exhibited weak fluorescence signals observed under microscopy while the positive group displayed a significant increase. Treatment with varying concentrations of ES-EV resulted in a notable reduction of intracellular ROS levels in HK-2 cells. Moreover, an increase in the concentration of ES-EV corresponded with a progressive decrease in intracellular ROS levels, approaching those observed in the control group (Fig. 2F). Flow cytometric analysis of ROS fluorescence further validated these observations (Fig. 2K, L). Additionally, live and dead cell staining demonstrated that prolonged accumulation of ROS led to cell death in the positive control group. Conversely, the ratio of dead to live cells decreased with ES-EV treatment, thereby substantiating the significant cytoprotective effect of ES-EV against ROS-induced cellular damage (Fig. 2G-H and Fig. S12). Excessive ROS production leads to oxidative stress-induced apoptosis, significantly contributing to tubular damage and dysfunction in AKI. Flow cytometric analysis using Annexin V-FITC and PI staining was utilized to distinguish apoptotic and necrotic cells. In the negative control group, apoptotic cells comprised less than 6%, while the positive group exhibited an apoptosis rate exceeding this by over 15 times and ES-EV treatment notably decreased the apoptotic cells (Fig. 2M-N). These findings underscore the potent antioxidant activity of ES-EV in preventing ROS-induced apoptosis in vitro. The changes in mitochondrial membrane potential (MMP) is linked to the initial phases of apoptosis [30]. The investigation analyzed MMP variations by employing JC-1, which accumulates and forms J aggregates in the mitochondrial matrix of cells with high MMP, causing intense red fluorescence. Treatment of the positive control group resulted in decreased red fluorescence and increased green fluorescence, signifying a reduction in MMP (Fig. 2I-J). The administration of ES-EV notably reduced the rise in green fluorescence, indicating its effectiveness in maintaining MMP and preventing apoptosis (Fig. S13). These findings were corroborated by flow cytometry analysis of JC-1 fluorescence (Fig. 2O-P). Collectively, these results underscore the potent antioxidant activity of ES-EV in preventing ROS-induced apoptosis in vitro. Of note, there is a difference between the higher concentration (mg/mL level) of ES-EVs required in the in vitro chemical free radical scavenging assay observed in this study and the lower concentration (µg/mL level) of ES-EVs that demonstrated protective effects in the cell model. This most likely reflects its different mechanism of action: in cell-free systems, it acts as a direct chemical scavenger; while inside the cell, it exerts powerful, amplified biological effects mainly by regulating the cell, thereby achieving cytoprotecting at even lower concentrations. Fig. 2ES-EV conferred protection to HK-2 cells against oxidative stress-induced damage. A) A schematic illustration demonstrates the protective role of ES-EV in mitigating ROS-induced injury in HK-2 cells. B) Images from CLSM display HK-2 cells exposed to Cy 5@ES-EV over different durations. C) Flow cytometry was employed to quantify the fluorescence intensity of Cy 5@ES-EV within HK-2 cells. D) The viability of HK-2 cells was assessed following exposure to different concentrations of ES-EV in an H2O2-induced oxidative stress model. E) Intracellular ROS levels were measured in HK-2 cells with and without ES-EV treatment. F) A quantitative assessment of intracellular ROS levels was performed. G) Representative images show live (green) and dead (red) cell staining after co-culture with varying concentrations of H2O2 and ES-EV. H) Quantitative analysis of the live/dead cell staining. I) Images showing fluorescence of JC-1 stained HK-2 cells after different treatments. J) Quantitative analysis of the JC-1 cell staining. K) Flow cytometry data and L) statistical analysis of ROS levels in HK-2 cells. M) Flow cytometry analysis and N) corresponding statistical evaluation were conducted on HK-2 cells with Annexin V/PI staining subjected to various treatment conditions. O) Flow cytometry analysis with JC-1 staining and P) subsequent statistical evaluation of HK-2 cells across various treatment conditions. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 ES-EV conferred protection to HK-2 cells against oxidative stress-induced damage. A) A schematic illustration demonstrates the protective role of ES-EV in mitigating ROS-induced injury in HK-2 cells. B) Images from CLSM display HK-2 cells exposed to Cy 5@ES-EV over different durations. C) Flow cytometry was employed to quantify the fluorescence intensity of Cy 5@ES-EV within HK-2 cells. D) The viability of HK-2 cells was assessed following exposure to different concentrations of ES-EV in an H2O2-induced oxidative stress model. E) Intracellular ROS levels were measured in HK-2 cells with and without ES-EV treatment. F) A quantitative assessment of intracellular ROS levels was performed. G) Representative images show live (green) and dead (red) cell staining after co-culture with varying concentrations of H2O2 and ES-EV. H) Quantitative analysis of the live/dead cell staining. I) Images showing fluorescence of JC-1 stained HK-2 cells after different treatments. J) Quantitative analysis of the JC-1 cell staining. K) Flow cytometry data and L) statistical analysis of ROS levels in HK-2 cells. M) Flow cytometry analysis and N) corresponding statistical evaluation were conducted on HK-2 cells with Annexin V/PI staining subjected to various treatment conditions. O) Flow cytometry analysis with JC-1 staining and P) subsequent statistical evaluation of HK-2 cells across various treatment conditions. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 The anti-inflammatory properties of ES-EV in vitro In light of the significant role of cisplatin-induced oxidative stress in influencing macrophage polarization within inflammation-related diseases, we conducted an in vitro investigation to assess the effects of ES-EV on macrophages [28]. According to the results of CCK-8 assays, lipopolysaccharide (LPS, 100 ng/mL) markedly increased the proliferation of RAW 264.7 cells. This proliferation exhibited a concentration-dependent decrease when treated with ES-EV concentrations in 5–20 µg/mL (Fig. S14). Macrophages are capable of adopting distinct functional phenotypes in response to their microenvironment, which are generally classified into M1 and M2 macrophages [31]. M1 macrophages enhance inflammation, whereas M2 macrophages play a role in regulating the immune system and remodeling tissues. RAW 264.7 cells were treated with LPS to induce M1 macrophage activation, as it is a recognized stimulus for this process [32]. Flow cytometry analysis revealed a significant decrease in the M1 macrophage population, indicated by CD86 expression, after incubation with ES-EV compared to the LPS-treated group (Fig. S15). Similarly, the group treated with 20 µg/mL ES-EV showed an increase in the CD206 biomarker, as revealed by flow cytometry analysis, when compared to the control group (Fig. S16-17). To further explore the necessity of synthesizing bio-hybrid nanovesicles, we conducted a comprehensive assessment of the anti-inflammatory properties of various components (Fig. 3I). Initially, RAW 264.7 cells were activated with LPS to simulate an inflammatory environment. Subsequently, the cells were treated with EV, ES NPs and ES-EV, respectively. An immunofluorescence analysis of M1 (CD86) and M2 (CD206) phenotype markers was carried out to determine the effects of these treatments on RAW 264.7 cells. Cells exposed to ES-EV showed a notable decrease in CD86 expression and an elevation in CD206 expression compared to other groups, indicating successful polarization from the M1 to M2 phenotype (Fig. 3A-D and Fig. S18). Flow cytometry analysis revealed that CD86 expression was elevated in LPS-treated groups compared to the control, whereas the ES-EV-treated group demonstrated a significant reduction in CD86 expression (49.7%) relative to the LPS-treated group (69%) (Fig. 3E-F). Notably, flow cytometry analysis of CD206 revealed that the ES-EV-treated group exhibited the most significant enhancement effect compared to the groups treated with EV or ES NPs (Fig. 3G-H and Fig. S19). Figure 3J-M shows that LPS treatment significantly elevated the mRNA expression levels of Cd86 and Nos2 compared to the control group. Conversely, treatment with ES-EV resulted in a reduction of Cd86 and Nos2 expression in LPS-stimulated RAW 264.7 cells when compared to the LPS, EV and ES NPs-treated groups. The expression levels of Cd206 and Arg-1 were substantially elevated in comparison to those in the LPS, EV and ES NPs-stimulated groups. Western blot analysis corroborated these findings, demonstrating a consistent trend in protein expression corresponding to the variations observed at the mRNA level (Fig. 3N-P and Fig. S20). The ES-EV treatment induced the most pronounced transition from M1 to M2, underscoring the superior inflammatory regulatory potential of the bio-hybrid product complexes. Fig. 3The anti-inflammatory properties of ES-EV in vitro. A) Immunofluorescent staining was performed on RAW 264.7 cells post-coculture with LPS and various treatments, including EV, ES NPs and ES-EV, to visualize CD86 (green) and DAPI (blue). B) Quantitative analysis of the CD86 and DAPI staining. C) Immunofluorescent staining of RAW 264.7 cells, post-coculture with LPS and various treatments (EV, ES NPs, and ES-EV), showing CD206 in green and DAPI in blue. D) Analysis of CD206 and DAPI staining in quantitative terms. E) Flow cytometry was performed using F4/80 and CD86 markers and F) corresponding statistical was conducted on RAW 264.7 cells subjected to various treatments. G) Flow cytometry analysis was conducted using F4/80 and CD206 markers and H) statistical analysis was performed on RAW 264.7 cells subjected to various treatments. I) Schematic illustration of the anti-inflammatory properties of ES-EV in vitro. J-M) The expression level of macrophage polarization-associated marker genes on Cd86 (J), Nos2 (K), Cd206 (L), Arg1 (M). N) Detection of the expression level of macrophage polarization-associated marker proteins. O-P) Quantitative analysis of CD206 (O) and iNOS (P). ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 The anti-inflammatory properties of ES-EV in vitro. A) Immunofluorescent staining was performed on RAW 264.7 cells post-coculture with LPS and various treatments, including EV, ES NPs and ES-EV, to visualize CD86 (green) and DAPI (blue). B) Quantitative analysis of the CD86 and DAPI staining. C) Immunofluorescent staining of RAW 264.7 cells, post-coculture with LPS and various treatments (EV, ES NPs, and ES-EV), showing CD206 in green and DAPI in blue. D) Analysis of CD206 and DAPI staining in quantitative terms. E) Flow cytometry was performed using F4/80 and CD86 markers and F) corresponding statistical was conducted on RAW 264.7 cells subjected to various treatments. G) Flow cytometry analysis was conducted using F4/80 and CD206 markers and H) statistical analysis was performed on RAW 264.7 cells subjected to various treatments. I) Schematic illustration of the anti-inflammatory properties of ES-EV in vitro. J-M) The expression level of macrophage polarization-associated marker genes on Cd86 (J), Nos2 (K), Cd206 (L), Arg1 (M). N) Detection of the expression level of macrophage polarization-associated marker proteins. O-P) Quantitative analysis of CD206 (O) and iNOS (P). ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 ES-EV shielded the kidneys from cisplatin-induced AKI in mice Given that ES-EV showed significant protection in cell experiments, we investigated the anti-renal injury effect of ES-EV in mice. First, we evaluated the distribution of ES-EVs in mice. As shown in Fig. S21, Cy5@ES-EV was intravenously administered to C57BL/6 mice to analyze its biodistribution across primary organs post-injection. The images revealed that ES-EV rapidly accumulated in the kidneys, reaching peak concentration within approximately one hour, thereby potentially enhancing its antioxidant effects. Research has demonstrated that early stages of renal disease are characterized by tubulointerstitial oxidative stress and inflammation [33, 34]. The targeted effect of ES-EV on the inflammatory site can alleviate renal tubular injury, repair renal tubular function and delay the progression of AKI. An AKI model was employed to assess the efficacy of ES-EV in reducing ROS-induced damage and restoring renal function. Male C57BL/6 mice were administered cisplatin intraperitoneally to establish a model of cisplatin-induced AKI. ES-EV was administered to the mice via the tail vein on three consecutive days post-cisplatin injection, and the mice were subsequently euthanized 72 h post-injection (Fig. 4A). The implementation of this protocol led to the accumulation of substances, including myoglobin, in the renal tissues via systemic circulation and metabolic processes, consequently causing oxidative damage and compromised renal function. Subsequent to the establishment of the AKI model, the mice were administered ES-EV. Key indicators of renal function, such as body weight, BUN and CRE levels, were subsequently assessed. (Fig. 4B-D). Compared with the cisplatin-treated group, both ES NPs and EV monotherapies modestly lowered serum BUN and CRE levels in mice, whereas ES‑EV combination therapy produced a significantly greater reduction in these renal injury markers and concurrently increased body weight, thereby confirming the robust therapeutic potential of ES-EV in the management of AKI. Histological analysis using hematoxylin and eosin (H&E) staining of kidney tissues from cisplatin-treated mice revealed histopathological injuries, including tubular casts with intratubular obstruction (Fig. 4E, indicated by black asterisks). Casts forming in renal tubules as a result of denatured protein precipitation are frequently a sign of kidney disorders [35]. Compared with the Cisplatin group, all three treatment groups (ES NPs, EV, and ES‑EV) attenuated renal tissue injury to varying degrees. The ES‑EV group exhibited the most pronounced improvement, showing a significant reduction in tubular dilatation, whereas the ES NPs and EV groups provided more modest protection. These findings underscore both the therapeutic potential of ES‑EVs and the value of engineering biomimetic nanovesicles for enhanced efficacy. (Fig. 4E). Tubulointerstitial injury arises from the excessive death of renal tubular epithelial cells and compromised tubular repair [36]. TUNEL staining yielded results consistent with the H&E observations: cisplatin‑treated mice exhibited a significantly higher number of apoptotic cells in renal tissues compared with the Blank group. All three treatment groups (ES NPs, EV, and ES‑EV) showed a reduction in apoptosis, with the ES‑EV group demonstrating the most pronounced decrease. These findings indicate that ES‑EV treatment effectively protects the kidney from cisplatin‑induced apoptotic damage. (Fig. 4F-G). Fig. 4ES-EV shielded the kidneys from cisplatin-induced AKI in mice. A) Protocol of ES-EV treatment in mice. B) Weight progression of mice across various groups. C) CRE and D) BUN levels for the specified groups. E) H&E-stained kidney section images from each group, indicating tubular casts (black asterisk). F) Each experimental group’s representative kidney sections were subjected to TUNEL staining analysis. G) Analysis of TUNEL assay outcomes. H-K) Serum levels of several inflammatory factors were quantified using ELISA for each group. L) Visual depiction of ES-EV’s protective effect on kidney injury caused by Cisplatin in mice through the regulation of the cGAS-STING signaling pathway. M) The expression levels of proteins the cGAS-STING signaling pathway in mouse kidneys. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 ES-EV shielded the kidneys from cisplatin-induced AKI in mice. A) Protocol of ES-EV treatment in mice. B) Weight progression of mice across various groups. C) CRE and D) BUN levels for the specified groups. E) H&E-stained kidney section images from each group, indicating tubular casts (black asterisk). F) Each experimental group’s representative kidney sections were subjected to TUNEL staining analysis. G) Analysis of TUNEL assay outcomes. H-K) Serum levels of several inflammatory factors were quantified using ELISA for each group. L) Visual depiction of ES-EV’s protective effect on kidney injury caused by Cisplatin in mice through the regulation of the cGAS-STING signaling pathway. M) The expression levels of proteins the cGAS-STING signaling pathway in mouse kidneys. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 In AKI, the dynamic polarization of macrophages is essential for controlling inflammation and the processes of damage and recovery [11]. The secretion of increased cytokine levels, such as TNF-α, IL-6, IFN-γ, and IL-1β, by proinflammatory macrophages contributes to the worsening of renal injury and nonbacterial inflammation [37]. In our initial assessment, the above proinflammatory cytokines have been measured, which revealed a significant upregulation of proinflammatory cytokines expression in mice with cisplatin-induced AKI compared to control mice. Notably, treatment with ES-EV led to the suppression of these inflammatory mediators, indicating that ES-EV effectively alleviates inflammatory pathological conditions and improves renal function (Fig. 4H-K). Previous research has identified cisplatin-induced mitochondrial dysfunction and the activation of the cGAS-STING pathway by mtDNA as critical regulators of kidney injury and inflammation [8, 38]. To clarify the molecular mechanisms behind the protective effects of ES-EV on kidney injury, we analyzed cGAS-STING markers (Fig. 4L). As anticipated, cisplatin treatment led to an upregulation of cGAS and STING expression at the protein level. Cisplatin exposure enhanced the activation of the cGAS-STING pathway, as evidenced by increased phosphorylation of downstream molecules TBK1 and IRF3 (Fig. 4M). Protein expression was significantly reduced in the ES-EV treatment group compared to the group treated with cisplatin, indicating that ES-EV might mitigate renal injury and inflammation by suppressing the cGAS-STING signaling pathway (Fig. 4M and Fig. S22). Our findings suggest that ES-EV can mitigate pro-inflammatory cytokine release and promote macrophage phenotypic transition from M1 to M2 by inhibiting cGAS-STING pathway activation. To evaluate this hypothesis, macrophage phenotypes were analyzed through immunofluorescence staining using CD86 as an M1 marker and CD206 as an M2 marker. As illustrated in Fig. 5A-D, cisplatin treatment resulted in strong CD86 fluorescence and weak CD206 fluorescence, indicating M1 polarization of macrophages. The fluorescence signal of CD86 decreased while CD206 increased, indicating an M1-to-M2 phenotype transition induced by ES-EV (Fig. S23). The findings show that ES-EV was effective in reducing inflammation and enhancing kidney function. The in vivo biosafety of ES-EV was further evaluated. Mice were continuously injected with ES-EV for 3 d, and subsequent experiments were performed on organs and blood 14 d later. As illustrated in Fig. S24, the ES-EV treated group and the control group showed no significant differences in the hemolysis assay indicated. More importantly, CRE and BUN of mice in the ES-EV-treated group were within the normal range and showed no significant nephrotoxicity in 14 days (Fig. S25). Serum concentrations of ALT and AST remained within normal physiological ranges, suggesting an absence of hepatotoxic effects attributable to ES-EV, as depicted in Fig. S26. Additionally, Fig. S27 reveals no significant differences in various inflammatory markers between the experimental groups. Long-term histological examination of renal and other organ tissues indicated no observable signs of pathological changes (Fig. S28). To further explore the metabolism of ES-EV in vivo, we injected Cy5@ES-EV from the tail vein of mice and quantitatively evaluated the distribution of ES-EV in major organs at 5 time points (1 h, 5 h, 10 h, 18 h and 24 h after injection). Fig. S29 A-B shows that ES-EV can accumulate in metabolic organs such as liver and kidney 1 h after entering the body, and it is almost completely cleared in the body 24 h later. Collectively, these results highlight the favorable biosafety profile of ES-EV in vivo. Fig. 5The regulation of the immune microenvironment of ES-EV in vivo. A) Kidney immunofluorescence images from each group illustrate F4/80 in green, CD86 in red, and DAPI in blue. B) Immunofluorescence quantification of F4/80 and CD86. C) Each group’s kidney immunofluorescence images reveal F4/80, CD206 (red), and DAPI. D) Immunofluorescence results of F4/80 and CD206. E) Flow cytometry analysis using F4/80 and CD86 markers, and F) corresponding evaluation of mouse spleens across various treatment conditions. G) Flow cytometry analysis was conducted on mouse spleens using F4/80 and CD206 staining under various treatment conditions. H) Corresponding statistical analysis of M1/M2 macrophage ratio. I) Flow cytometry analysis of CD80 and CD11c staining and J) statistical evaluation was conducted on mice spleens subjected to various treatments. K) Flow cytometry analysis of CD8 and CD3 markers and L) corresponding statistical evaluation were conducted on mouse spleens under various treatment conditions. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 The regulation of the immune microenvironment of ES-EV in vivo. A) Kidney immunofluorescence images from each group illustrate F4/80 in green, CD86 in red, and DAPI in blue. B) Immunofluorescence quantification of F4/80 and CD86. C) Each group’s kidney immunofluorescence images reveal F4/80, CD206 (red), and DAPI. D) Immunofluorescence results of F4/80 and CD206. E) Flow cytometry analysis using F4/80 and CD86 markers, and F) corresponding evaluation of mouse spleens across various treatment conditions. G) Flow cytometry analysis was conducted on mouse spleens using F4/80 and CD206 staining under various treatment conditions. H) Corresponding statistical analysis of M1/M2 macrophage ratio. I) Flow cytometry analysis of CD80 and CD11c staining and J) statistical evaluation was conducted on mice spleens subjected to various treatments. K) Flow cytometry analysis of CD8 and CD3 markers and L) corresponding statistical evaluation were conducted on mouse spleens under various treatment conditions. ns meant p > 0.05, * meant p < 0.05, ** meant p < 0.01, *** meant p < 0.001, **** meant p < 0.0001 Utilizing flow cytometry, we assessed the immune tolerance response elicited by bio-hybrid nanovesicles, specifically ES-EV, to confirm their capacity to modulate the immune microenvironment. This evaluation included the regulation of innate immunity, antigen presentation, and adaptive immunity (Fig. S30-32). Notably, Fig. 5E, G illustrate a significant shift in macrophage polarization of mice treated with ES-EV. Further quantification of M1 and M2 macrophages corroborated this finding (Fig. 5F, H and Fig. S33). Comparative analysis of splenic DCs across groups revealed a reduced proportion of mature DCs in the ES-EV group (Fig. 5I-J), indicating that ES-EV can inhibit DC maturation, thereby maintaining them in an immature state conducive to immune tolerance. We designate these immune-tolerant DCs as tDCs. The tDCs demonstrated the ability to suppress excessive immune activation in mice with AKI. This observation led us to further investigate alterations in the CD8+ T cell populations within the spleen. As depicted in Fig. 5K-L, ES-EV treatment effectively mitigated T cell overactivation. In summary, ES-EV can modulated inflammatory immune responses in AKI mice, driving autoimmunity and subsequently promoting effective specific immune tolerance. Fig. 6RNA sequencing (RNA-seq) reveals the therapeutic effects of ES-EV on cisplatin-AKI. A) Three-dimensional Principal Component Analysis (PCA) score plot of samples. B-C) The volcano plot demonstrates the arrangement of differentially expressed genes (DEGs) in comparisons Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. D-E) The expression patterns of DEGs in Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. F) The UpSet plot depicts the concordance of upregulated and downregulated DEGs in two comparison groups. G-H) Biological process (BP) enrichment of common upregulated and downregulated genes in Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. I) Interferon response related DEGs RNA sequencing (RNA-seq) reveals the therapeutic effects of ES-EV on cisplatin-AKI. A) Three-dimensional Principal Component Analysis (PCA) score plot of samples. B-C) The volcano plot demonstrates the arrangement of differentially expressed genes (DEGs) in comparisons Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. D-E) The expression patterns of DEGs in Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. F) The UpSet plot depicts the concordance of upregulated and downregulated DEGs in two comparison groups. G-H) Biological process (BP) enrichment of common upregulated and downregulated genes in Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV. I) Interferon response related DEGs RNA-seq reveals the therapeutic effects of ES-EV on cisplatin-induced AKI To thoroughly investigate cisplatin-induced nephrotoxicity and the ameliorative effects of ES-EV on renal injury, we assessed alterations in gene expression across the Blank, cisplatin and cisplatin + ES-EV cohorts. PCA showed high reproducibility of samples within each group (Fig. 6A). In the comparison between the Cisplatin and Blank groups, we identified 2,798 upregulated and 2,153 downregulated genes (Fig. 6B). Furthermore, to examine the mitigating effects of ES-EV on cisplatin-induced damage, we compared the ES-EV treatment group with the cisplatin injury group, identifying 1,274 upregulated and 1,248 downregulated genes (Fig. 6C). The expression patterns of differentially expressed genes in both comparison groups (Cisplatin vs. Blank and Cisplatin vs. Cisplatin + ES-EV) exhibited strong intra-group consistency (Fig. 6D-E), further confirming the high reproducibility of the study sample groups. In order to examine the molecular mechanisms by which ES-EV eases kidney injury induced by cisplatin, we divided the differentially expressed genes from the comparison groups into up-regulated and down-regulated categories. Subsequently, we analyzed the consistent changes in these genes across the comparison groups. Our analysis identified a total of 2,336 differentially expressed genes common to both groups, with 2,329 exhibiting a consistent trend: 1,195 genes were simultaneously up-regulated, while 1,134 were concurrently down-regulated (Fig. 6F). These genes, which display similar expression patterns, are likely implicated in the ES-EV-mediated treatment of cisplatin-induced kidney injury. Furthermore, enrichment analysis of the up-regulated genes revealed significant associations with inflammation, interferon-related pathways, ROS, oxidative stress, DNA damage, and apoptosis. These findings suggest that ES-EV may mitigate cisplatin-induced oxidative stress and DNA damage while concurrently exerting anti-inflammatory effects (Fig. 6G). Furthermore, the concurrently down-regulated genes were predominantly associated with metabolism-related pathways, including those involved in small molecule metabolism, fatty acid metabolism, and transport-related pathways (Fig. 6H). Notably, glutathione is integral to the antioxidant process, and the significant enrichment of glutathione metabolic engineering in down-regulated genes further substantiates the efficacy of ES-EV in mitigating oxidative stress. Additionally, an analysis of interferon-related pathway genes revealed that ES-EV has the capacity to reverse the expression of Sting1, Cgas, and other related genes (Fig. 6I). The limitations of the study Despite the promising therapeutic efficacy demonstrated by ES-EV, there are some limitations of this study. Firstly, ES-EV was found to accumulate not only in the kidney, but also in the liver and spleen after systemic administration, which may be due to the following factors: (i) ES-EV entered the body through tail vein injection and was eliminated by mononuclear phagocyte system (MPS) in the liver and spleen; (ii) ES-EV are mainly used for passive targeting of inflammatory sites through the inflammatory tropism of hUMSC‑EVs. Therefore, there may be a risk of off-target. However, ES-EV demonstrated excellent biosafety in blood compatibility tests as well as H&E staining tests in major organs, the off-target effects did not cause damage to the organism. More importantly, because cisplatin is not only nephrotoxic but also induces systemic monocyte activation and inflammation in vivo, the inflammatory tropism of ES-EV may also make it a better immunomodulatory agent in macrophage-rich organs despite the risk of off-target effects. The spleen can often represent the whole immune microenvironment in the body due to its abundant blood supply and immune cells. Therefore, we also examined the immune cells in the spleen of mice, and the experimental results also showed that ES-EV had a good regulatory effect on spleen immune cells. In conclusion, although ES-EV do not cause injury in mice due to off-target effects or off-target immune modulation, subsequent studies could focus on active renal targeting to further enhance the specificity of treatment. In addition, there are several challenges must be addressed before clinical translation can be realized: (i) achieving large‑scale manufacturing under current Good Manufacturing Practice (cGMP) conditions, and (ii) controlling batch‑to‑batch and donor‑to‑donor variability. Recent advances have established scalable production platforms that enable batch manufacturing using bioreactor‑based systems combined with downstream processing; nevertheless, further efforts are needed to define how such platforms can be implemented for phase I/II trials of EV‑based therapies [39]. Donor‑to‑donor variability in EV composition can be mitigated through stringent donor selection criteria, the use of standardized cell banks, and, more recently, the development of immortalized MSC lines that provide an unlimited and uniform source of EVs [40]. Importantly, a growing consensus now recommends dual‑metric dosing (particles plus protein) coupled with mechanism‑aligned potency assays to ensure batch‑to‑batch consistency and to facilitate the clinical translation of EV‑based therapeutics [41]. Collectively, we believe that addressing these issues is critical for advancing the clinical application of EVs. Conclusion Currently, the clinical studies that suggest that oxidative stress is a pathogenic driver of AKI in humans. Patients with AKI have persistently elevated urinary and plasma biomarkers of oxidative damage, including 8-hydroxy-2’-deoxyguanosine, F2-isoprostane and malondialdehyde, which correlate with disease severity and poor outcomes [42, 43]. Mechanistically, excessive ROS in human AKI trigger mitochondrial dysfunction, lipid peroxidation, and DNA damage in proximal tubular cells, leading to necroptosis, ferroptosis, and activation of pro-inflammatory signaling pathways such as NF-κB and NLRP3 inflammasome [44–46]. In addition, genetic polymorphisms in antioxidant enzymes such as glutathione peroxidase 1, superoxide dismutase 2 and catalase are associated with increased susceptibility to AKI in high-risk populations such as critically ill patients and those receiving cisplatin chemotherapy [47, 48]. These clinical evidences suggest that ROS is not only a biomarker of AKI in humans, but also a potential therapeutic target. In addition to oxidative stress and inflammatory response, which have been widely studied, immune stress also plays an important role in the development of AKI. Accumulating evidence suggests that CD8⁺ T cells are key drivers of acute kidney injury and disease progression. In cisplatin-induced AKI, CD8⁺ T cells infiltrate the damaged kidney, activate and directly cause tubular injury. Mechanistically, they promote the transition from AKI to chronic kidney disease (CKD) by inducing perivascular capillary thinning through the Fas ligand-Fas signaling pathway. CD8⁺ T cells are recruited to the kidney via the macrophage-mediated CXCL16-CXCR6 pathway, and depletion of CD8⁺ T cells has been shown to ameliorate capillary rarefaction and subsequent fibrosis. In addition, CD8⁺ T cells directly damage renal tubular epithelial cells by releasing proinflammatory cytokines such as TNF-α and IFN-γ [49]. Importantly, Clinical studies have shown that elevated levels of activated CD8⁺ T lymphocytes are observed in kidney transplant recipients with early acute tubular injury [50]. Taken together, these findings suggest that simultaneous modulation of oxidative stress, inflammatory homeostasis and immune microenvironment has promising applications in the treatment of AKI. In this study, we have successfully developed ES-EV biohybrid vesicles that synergistically combines the dual antioxidant and inflammation modulatory capacities of ES NP with the intrinsic bioactivity of hUMSC-EV. The ES-EV system demonstrates: (1) SOD-like activity and superior ROS scavenging efficiency; (2) inhibition of mtDNA-activated cGAS-STING pathway to regulate macrophage phenotype and enhance the ability to regulate inflammatory homeostasis; (3) the ability to reprogram the immune microenvironment by regulating DCs and T cells. In vitro assessments confirmed ES-EV’ s ability to mitigate oxidative stress, suppress apoptosis, and polarize macrophages toward anti-inflammatory M2 phenotypes, thereby preventing excessive inflammatory cascades. In vivo experiments have shown that ES-EV could protect against cisplatin-induced renal injury and inhibit apoptosis. In addition, ES-EV could also inhibit the cisplatin-activated cGAS-STING pathway to reduce the release of inflammatory factors such as IL-6, IL-1β, TNF-α and IFN-γ, thereby reducing the M1-type polarization of macrophages infiltrating the kidneys and achieving the goal of maintaining the balance of the renal immune microenvironment. In conclusion, ES-EV could reshape the immune microenvironment and treat kidney injury by regulating oxidative stress and maintaining inflammatory homeostasis. This study establishes a prototype of a natural product-EV complex with multifunctional therapeutic properties and has the potential to pave the way for clinical translation of precise management of AKI. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1